Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Amortizatization of Intangibles (2024 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Amortizatization of Intangibles for 2 consecutive years, with -$1.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortizatization of Intangibles fell 287.53% year-over-year to -$1.7 million, compared with a TTM value of $602000.0 through Dec 2025, down 32.36%, and an annual FY2025 reading of $602000.0, down 32.36% over the prior year.
  • Amortizatization of Intangibles was -$1.7 million for Q4 2025 at Zevra Therapeutics, down from $1.2 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $1.2 million in Q3 2025 and bottomed at -$1.7 million in Q4 2025.